Eli Lilly sues companies selling alternative versions of its weight loss drug
Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.
Compounded drugs aren’t generics. Rather, they are essentially copies that are allowed to be made by special pharmacies called compounding pharmacies during drug shortages. Tirzepatide, the active ingredient in Lilly’s Zepbound and Mounjaro for Type 2 diabetes, was in shortage for two years until Dec. 19, 2024. The U.S. Food and Drug Administration required an end to making the copies by mid-March, but pharmacies could sell stock already produced until it ran out or expired. And compounders can generally make custom drugs for patients with a doctor’s prescription as they do for patients with allergies to certain preservatives in medications, for example.
During the Zepbound shortage, compounding pharmacies filled the gap for patients who couldn’t find the brand name drug in their pharmacies and patients who didn’t have insurance coverage for the drug and couldn’t afford Zepbound sticker price of more than $1,086.37 a month. For comparison, compounded tirzepatide sells for as little as $99 a month.
Now, the tirzepatide shortage is over and deadlines for producing new copies of tirzepatide have passed, Eli Lilly is cracking down.
“Anyone continuing to sell mass compounded tirzepatide is breaking the law and deceiving patients,” Lilly said in a company statement sent to NPR. “We will continue to take action to stop those who threaten patient safety and urgently call on regulators and law enforcement to do the same.”
Eli Lilly filed lawsuits against compounding pharmacies earlier this month. Now, it has turned its attention to telehealth companies selling compounded tirzepatide. On Wednesday, Lilly filed complaints against Mochi Health, Willow Health, Fella Health and Delilah, and Henry Meds.
According to one complaint, Mochi allegedly switched its patients to compounded tirzepatide with different additives, like niacinamide. The complaint also alleges they switched patients over to different doses than those offered by Eli Lilly. These changes were made “at least five times in just eight months,” alleges the complaint, to enable Mochi to keep selling compounded tirzepatide.
The existing law prohibits compounders from making “essentially” a copy of an existing commercially available drug.
Mochi representatives did not respond to requests for comment.
Lilly’s complaint against Henry Meds alleges the telehealth company improperly referenced Lilly’s approved drugs and clinical trials on its website in order to sell more compounded versions. Henry Meds and Fella Health are also accused of selling tirzepatide in pill form, which has never been approved by the FDA. “Fella even tells patients that its untested oral drug is better than Lilly’s approved medicines,” Lilly’s complaint against Fella alleges.
And the complaint against Willow Health asserts that Willow falsely claimed to have developed the first “cosmetic” GLP-1. “FDA has never approved any form of tirzepatide for cosmetic weight loss,” Lilly’s complaint alleges, adding that Lilly makes the only FDA-approved tirzepatide.
Henry Meds, Fella Health and Willow Health did not respond to NPR’s requests for comment.
On April 1, Eli Lilly sued two compounding pharmacies: Strive and Empower. Strive tells NPR it will fight back, and Empower says in a statement posted to its website, “We stand by our mission, and the patients and providers who depend on it.”
Scott Brunner, the CEO of the Alliance for Pharmacy Compounding, an advocacy group for compounding pharmacies, declined to comment on the specific suits or companies. However, in an email to NPR, he explained that compounders only produce drugs when a prescriber sends a prescription.
“I fear there is not a bright line on this issue of corporate practice of medicine vs. legitimate customization of a drug based on the judgment of a prescriber who has actually interacted with a patient,” he wrote. “FDA guidance clearly authorizes the latter, but the former is to a certain degree in the eye of the beholder. In these new Lilly lawsuits, [it] looks like the beholder will be a Federal judge.”
How Alabama Power kept bills up and opposition out to become one of the most powerful utilities in the country
In one of the poorest states in America, the local utility earns massive profits producing dirty energy with almost no pushback from state regulators.
No more Elmo? APT could cut ties with PBS
The board that oversees Alabama Public Television is considering disaffiliating from PBS, ending a 55-year relationship.
Nonprofit erases millions in medical debt across Gulf South, says it’s ‘Band-Aid’ for real issue
Undue Medical Debt has paid off more than $299 million in medical debts in Alabama. Now, the nonprofit warns that the issue could soon get worse.
Roy Wood Jr. on his father, his son and his new book
Actor, comedian and writer Roy Wood Jr. is out with a new book -- "The Man of Many Fathers: Life Lessons Disguised as a Memoir." He writes about his experience growing up in Birmingham, losing his dad as a teenager and all the lessons he learned from various father figures throughout his career.
Auburn fires coach Hugh Freeze following 12th loss in his last 15 SEC games
The 56-year-old Freeze failed to fix Auburn’s offensive issues in three years on the Plains, scoring 24 or fewer points in 17 of his 22 league games. He also ended up on the wrong end of too many close matchups, including twice this season thanks partly to questionable calls.
In a ‘disheartening’ era, the nation’s former top mining regulator speaks out
Joe Pizarchik, who led the federal Office of Surface Mining Reclamation and Enforcement from 2009 to 2017, says Alabama’s move in the wake of a fatal 2024 home explosion increases risks to residents living atop “gassy” coal mines.
